Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News Notable Notes: Will Rising Rupee Continue To Hold Back Retooled Indian Pharma Firms?

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - A confluence of new revenues from contract research and manufacturing services, in-license deals from multinational drug firms, vigorous efforts to discover new drugs, a slew of successful patent challenges and an upbeat outlook for generic drug demand, make leading Indian pharma companies attractive investments in a downbeat global economy, according to a 55-page report by IDFC-SSKI, the investment banking subsidiary of Mumbai-based Infrastructure Development Finance Company
Advertisement

Related Content

As Market Crashes, India’s Wockhardt Is Pushed To Consider Equity Dilution To Raise Funds To Repay Debts
As Market Crashes, India’s Wockhardt Is Pushed To Consider Equity Dilution To Raise Funds To Repay Debts
Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability
Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability
PharmAsia News India Pharma Roundup: Lupin, Strides Arcolab, GSK India, Nicholas Piramal, Jubilant
PharmAsia News India Pharma Roundup: Lupin, Strides Arcolab, GSK India, Nicholas Piramal, Jubilant
Ranbaxy And Teva Expected To Team Up For At Risk Launch Of Generic Nexium - Analysts
Ranbaxy And Teva Expected To Team Up For At Risk Launch Of Generic Nexium - Analysts
Biocon Partners With Biotech Startup In Latest India-U.S. Deal
Advertisement
UsernamePublicRestriction

Register

SC068099

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel